Uncategorized
Medicare, insurance beneficiaries have improved access to uveal melanoma test
Three important access milestones for DecisionDx-UM have been reached, Castle Biosciences announced in a press release.DecisionDx-UM, a prognostic test for uveal melanoma, has been issued a final local coverage determination from Palmetto GBA, effective July 10, 2017, improving access to the test for Medicare patients.